|
Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2014
|
Sep. 30, 2014
|
Jun. 30, 2014
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Jun. 30, 2013
|
|
| Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) [Line Items] | ||||||||||||
| Research and Development Expense | $ 41,884 | $ 33,221 | $ 22,001 | |||||||||
| Fair Value Adjustment of Warrants | (796) | (2,327) | (25,520) | |||||||||
| Other Operating Income (Expense) [Member] | Warrant [Member] | ||||||||||||
| Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) [Line Items] | ||||||||||||
| Fair Value Adjustment of Warrants | 300 | 1,300 | 1,700 | 2,500 | 1,200 | 200 | 1,600 | 300 | ||||
| Upfront Payment [Member] | Array BioPharma Inc. [Member] | ||||||||||||
| Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) [Line Items] | ||||||||||||
| Research and Development Expense | 20,000 | |||||||||||
| Fair Value Adjustment of Warrants | $ 10,000 | |||||||||||